Clinical Trial

Assessing PI3K Gamma Inhibition With Azacitidine, Venetoclax and Eganelisib in Patients With Acute Myeloid Leukemia

Study acronym: GAVEL
Not Yet Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This study is to evaluate the safety and preliminary efficacy of adding the PI3K-gamma inhibitor, eganelisib, to a standard of care treatment option with combination venetoclax and azacitidine in participants with acute myeloid leukemia (AML). The names of the study drugs involved in this research study are: * Venetoclax (a type of BCL-2 inhibitor) * Azacitidine (a type of Demethylating Agent) * Eganelisib (a type of PI3K-gamma inhibitor)
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-02-26.
Trial Details
NCT Number NCT07439211
Lead Sponsor Jacqueline Garcia, MD
Collaborators: Stelexis BioSciences, Inc.
Conditions Leukemia, Myeloid, Leukemia, Acute Myeloid Leukemia, Refractory Leukemia
Enrollment 48 participants
Start Date 2026-07
Primary Completion 2028-02-01 (estimated)
Study Completion 2029-02-01 (estimated)
Updated on ClinicalTrials.gov 2026-03-03